France · Delayed Price · Currency is EUR Nanobiotix Statistics
Total Valuation
Nanobiotix has a market cap or net worth of EUR 1.59 billion. The enterprise value is 1.63 billion.
| Market Cap | 1.59B |
| Enterprise Value | 1.63B |
Important Dates
The next estimated earnings date is Friday, June 5, 2026.
| Earnings Date | Jun 5, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Nanobiotix has 50.71 million shares outstanding. The number of shares has increased by 1.17% in one year.
| Current Share Class | 50.71M |
| Shares Outstanding | 50.71M |
| Shares Change (YoY) | +1.17% |
| Shares Change (QoQ) | +1.69% |
| Owned by Insiders (%) | 3.14% |
| Owned by Institutions (%) | 13.39% |
| Float | 33.35M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 48.64 |
| PB Ratio | -18.76 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -67.94 |
| EV / Sales | 49.95 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | -47.94 |
Financial Position
The company has a current ratio of 1.09
| Current Ratio | 1.09 |
| Quick Ratio | 1.05 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | -2.81 |
| Interest Coverage | -1.05 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | -10.06% |
| Return on Invested Capital (ROIC) | n/a |
| Return on Capital Employed (ROCE) | -106.13% |
| Weighted Average Cost of Capital (WACC) | 7.50% |
| Revenue Per Employee | 325,930 |
| Profits Per Employee | -239,610 |
| Employee Count | 100 |
| Asset Turnover | 0.48 |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, Nanobiotix has paid 3,000 in taxes.
| Income Tax | 3,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +714.60% in the last 52 weeks. The beta is 0.58, so Nanobiotix's price volatility has been lower than the market average.
| Beta (5Y) | 0.58 |
| 52-Week Price Change | +714.60% |
| 50-Day Moving Average | 31.41 |
| 200-Day Moving Average | 21.38 |
| Relative Strength Index (RSI) | 40.19 |
| Average Volume (20 Days) | 343,101 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Nanobiotix had revenue of EUR 32.59 million and -23.96 million in losses. Loss per share was -0.50.
| Revenue | 32.59M |
| Gross Profit | 32.59M |
| Operating Income | -10.88M |
| Pretax Income | -23.96M |
| Net Income | -23.96M |
| EBITDA | -10.49M |
| EBIT | -10.88M |
| Loss Per Share | -0.50 |
Balance Sheet
The company has 52.75 million in cash and 95.32 million in debt, with a net cash position of -42.57 million or -0.84 per share.
| Cash & Cash Equivalents | 52.75M |
| Total Debt | 95.32M |
| Net Cash | -42.57M |
| Net Cash Per Share | -0.84 |
| Equity (Book Value) | -84.48M |
| Book Value Per Share | -1.75 |
| Working Capital | 5.24M |
Cash Flow
In the last 12 months, operating cash flow was -33.42 million and capital expenditures -538,000, giving a free cash flow of -33.96 million.
| Operating Cash Flow | -33.42M |
| Capital Expenditures | -538,000 |
| Depreciation & Amortization | 393,000 |
| Net Borrowing | 38.19M |
| Free Cash Flow | -33.96M |
| FCF Per Share | -0.67 |
Margins
Gross margin is 100.00%, with operating and profit margins of -33.39% and -73.52%.
| Gross Margin | 100.00% |
| Operating Margin | -33.39% |
| Pretax Margin | -73.51% |
| Profit Margin | -73.52% |
| EBITDA Margin | -32.18% |
| EBIT Margin | -33.39% |
| FCF Margin | n/a |
Dividends & Yields
Nanobiotix does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -1.17% |
| Shareholder Yield | -1.17% |
| Earnings Yield | -1.51% |
| FCF Yield | -2.14% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Analyst Forecast
The average price target for Nanobiotix is 46.00, which is 52.62% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | 46.00 |
| Price Target Difference | 52.62% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 5 |
| Revenue Growth Forecast (3Y) | n/a |
| EPS Growth Forecast (3Y) | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Nanobiotix has an Altman Z-Score of 1.11 and a Piotroski F-Score of 2. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 1.11 |
| Piotroski F-Score | 2 |